BR112021005525A2 - combinação farmacêutica para o tratamento de câncer - Google Patents
combinação farmacêutica para o tratamento de câncer Download PDFInfo
- Publication number
- BR112021005525A2 BR112021005525A2 BR112021005525-8A BR112021005525A BR112021005525A2 BR 112021005525 A2 BR112021005525 A2 BR 112021005525A2 BR 112021005525 A BR112021005525 A BR 112021005525A BR 112021005525 A2 BR112021005525 A2 BR 112021005525A2
- Authority
- BR
- Brazil
- Prior art keywords
- antagonist
- sfrp2
- mab
- cells
- hsfrp2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737155P | 2018-09-27 | 2018-09-27 | |
| US62/737,155 | 2018-09-27 | ||
| PCT/US2019/053651 WO2020069439A1 (en) | 2018-09-27 | 2019-09-27 | Pharmaceutical combination for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021005525A2 true BR112021005525A2 (pt) | 2021-06-29 |
Family
ID=69953118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021005525-8A BR112021005525A2 (pt) | 2018-09-27 | 2019-09-27 | combinação farmacêutica para o tratamento de câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210395351A1 (https=) |
| EP (1) | EP3856784A4 (https=) |
| JP (1) | JP7451506B2 (https=) |
| KR (1) | KR102947706B1 (https=) |
| CN (2) | CN119818670A (https=) |
| AU (1) | AU2019351267A1 (https=) |
| BR (1) | BR112021005525A2 (https=) |
| CA (1) | CA3114173A1 (https=) |
| IL (1) | IL281782A (https=) |
| MX (1) | MX2021003274A (https=) |
| SG (1) | SG11202102865WA (https=) |
| WO (1) | WO2020069439A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114269376A (zh) * | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
| WO2025199292A1 (en) * | 2024-03-21 | 2025-09-25 | Musc Foundation For Research Development | A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011523551A (ja) * | 2008-05-15 | 2011-08-18 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 血管形成の調節の新規ターゲット |
| WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
| US9759725B2 (en) * | 2012-08-02 | 2017-09-12 | Fred Hutchinson Cancer Research Center | Treatment-induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins |
| EA037548B1 (ru) * | 2015-06-24 | 2021-04-12 | Янссен Байотек, Инк. | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 |
| JP2018518526A (ja) * | 2015-06-25 | 2018-07-12 | アドバンスド アクセレレーター アプリケーションズ | ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法 |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
| ES3034233T3 (en) * | 2016-01-22 | 2025-08-14 | MabQuest SA | Non-blocking pd1 specific antibodies |
| EP3582811B1 (en) | 2017-02-14 | 2024-07-10 | Novartis AG | Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination |
-
2019
- 2019-09-27 CN CN202411827485.1A patent/CN119818670A/zh active Pending
- 2019-09-27 WO PCT/US2019/053651 patent/WO2020069439A1/en not_active Ceased
- 2019-09-27 KR KR1020217012004A patent/KR102947706B1/ko active Active
- 2019-09-27 AU AU2019351267A patent/AU2019351267A1/en active Pending
- 2019-09-27 US US17/279,857 patent/US20210395351A1/en active Pending
- 2019-09-27 SG SG11202102865WA patent/SG11202102865WA/en unknown
- 2019-09-27 CN CN201980076608.3A patent/CN113454114B/zh active Active
- 2019-09-27 MX MX2021003274A patent/MX2021003274A/es unknown
- 2019-09-27 CA CA3114173A patent/CA3114173A1/en active Pending
- 2019-09-27 JP JP2021517299A patent/JP7451506B2/ja active Active
- 2019-09-27 BR BR112021005525-8A patent/BR112021005525A2/pt unknown
- 2019-09-27 EP EP19866195.1A patent/EP3856784A4/en active Pending
-
2021
- 2021-03-24 IL IL281782A patent/IL281782A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102947706B1 (ko) | 2026-04-03 |
| AU2019351267A1 (en) | 2021-05-13 |
| JP2022502434A (ja) | 2022-01-11 |
| WO2020069439A1 (en) | 2020-04-02 |
| JP7451506B2 (ja) | 2024-03-18 |
| MX2021003274A (es) | 2021-09-28 |
| SG11202102865WA (en) | 2021-04-29 |
| CN113454114B (zh) | 2024-12-27 |
| EP3856784A1 (en) | 2021-08-04 |
| EP3856784A4 (en) | 2022-10-19 |
| CN119818670A (zh) | 2025-04-15 |
| KR20210065146A (ko) | 2021-06-03 |
| IL281782A (en) | 2021-05-31 |
| US20210395351A1 (en) | 2021-12-23 |
| CA3114173A1 (en) | 2020-04-02 |
| CN113454114A (zh) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240066123A1 (en) | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody | |
| ES2813580T3 (es) | Composiciones que comprenden una combinación de ipilimumab y nivolumab | |
| ES2725463T3 (es) | Tratamientos combinados con anticuerpos anti-CD40 | |
| ES2989007T3 (es) | Terapia contra el cáncer de ovarios basada en agente anti-CD47 | |
| ES2992868T3 (en) | Combination of tim-4 antagonist and pd-1 antagonist and methods of use | |
| US20210107989A1 (en) | Methods for treating cd73hi tumors | |
| US10335494B2 (en) | Combination of aurora kinase inhibitors and anti-CD30 antibodies | |
| BR112019022695A2 (pt) | Formulações estáveis de anticorpos anti-ctla4 isolados e em combinação com anticorpos do receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
| BR112019018043A2 (pt) | método de tratamento de câncer, e, conjugado de anticorpo-fármaco | |
| BR112020025476A2 (pt) | Métodos para tratamento de câncer com anticorpos anti-cd3xmuc16 bispecífico e anticorpos anti-pd-1 | |
| KR20150130318A (ko) | 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법 | |
| KR20210034613A (ko) | 퀴놀린 유도체 및 항체의 약물 조합 | |
| JP2021521143A (ja) | がん処置のためのａｘｌ特異的抗体 | |
| BR112020013144A2 (pt) | Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer | |
| BR112021001796A2 (pt) | método para tratar câncer por combinação de inibidor de iap e modulador de molécula de ponto de verificação imunológico | |
| BR112020015142A2 (pt) | Anticorpos mica/b e métodos de uso | |
| ES2674491T3 (es) | Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos | |
| JP2026511501A (ja) | がんを処置するための抗体又はその抗原結合断片の組み合わせ及びその組成物 | |
| BR112021005525A2 (pt) | combinação farmacêutica para o tratamento de câncer | |
| BR112021000169A2 (pt) | Ministração de inibidor de enzima ativadora de sumo e anticorpos anti-cd20 | |
| TW202430566A (zh) | 一種包含特異性結合ｈｇｆｒ和ｅｇｆｒ的雙特異性抗體的醫藥組成物 | |
| US20230121867A1 (en) | Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation | |
| Obeid | Anticancer activity of targeted proapoptotic peptides and chemotherapy is highly improved by targeted cell surface calreticulin–inducer peptides | |
| RU2838216C2 (ru) | Фармакологическая комбинация для лечения рака | |
| HK40122434A (zh) | 治疗癌症的药物组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |